SOLUTRANS
26.10.2021 08:02:12 CEST | Business Wire | Press release
SOLUTRANS , the global hub for heavy and light commercial vehicles, will hold its 16th edition from 16 to 20 November 2021 in Lyon Eurexpo (France). Nearly 60,000 professionals, 1,000 exhibitors and brands are expected to attend this international event focusing on economic recovery and innovation, certified by the OICA (International Organization of Motor Vehicle Manufacturers).
This edition will showcase two major additions. Firstly, a "SOLUTRANS 4.0" hall dedicated to innovation for transport professionals. Secondly, the chance for professionals from all over the world to take part in the show remotely via the SOLUTRANS DIGITAL SHOW.
HGV manufacturers will be in attendance
The leading HGV manufacturers, such as DAF, IVECO, MAN, Mercedes, Renault Trucks, SCANIA and VOLVO will be exhibiting at SOLUTRANS. The largest bodywork manufacturers, vehicle fitters and service companies will also be present, as well as new names in the sector such as FORD TRUCKS, IRIZAR and VOLTA TRUCKS, who will be taking part for the first time in France.
SOLUTRANS 4.0, the hall of new technologies
This hall will present disruptive innovations and new names in the sector in all areas, from engineering to industry as well as IT solutions.
The objective of SOLUTRANS 4.0 is to foster the implementation of new solutions to optimize activity and overcome the challenges in the sector: energy transition, artificial intelligence, cybersecurity, recycling, etc.
Innovation gets the green light at SOLUTRANS !
All the innovations will be presented during the various award ceremonies that will take place during the trade show. The I-nnovation Awards have been further enriched this year and include a new prize: the "Digital AWARD". Also, for the fourth consecutive edition, SOLUTRANS will host the International Awards: ITOY, IVOTY, IPUA and TRUCK INNOVATION AWARD. These awards, recognized by the industry as a whole, reward the excellence of manufacturers and showcase the trends in the industrial and urban vehicle sector.
The theme of innovation will also be highlighted during the event via a broad range of conferences covering a variety of topics that respond to the challenges of the sector.
Finally, SOLUTRANS, in partnership with TotalEnergies, will be offering a new, completely redesigned and larger testing area to meet the needs of visitors and manufacturers of heavy and light commercial vehicles. The track has also been extended and re-designed with a 25 km semi-urban route to allow professionals to test the vehicles around the park.
SOLUTRANS DIGITAL SHOW: unlimited online access to the trade show
The SOLUTRANS DIGITAL SHOW, the virtual edition of the physical exhibition, will offer registered visitors, wherever they are located in the world, an interactive space where they can visit exhibitors' stands, contact their representatives and discover their new products… it’s all just click away! Two weeks before the actual trade show, registered visitors will be able to start making appointments with exhibitors and take advantage of the three additional days of opening to consult an exhibitor's offer online, thus giving them a chance to contact businesses that they wouldn’t have had time to meet during the physical edition of the trade show. They will also have access to conferences and other events, which will be broadcast live.
Discover the whole program of the SOLUTRANS 2021 trade show on solutrans.eu
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005031/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom